Corporate & Industry News - 18-January-2018
Consultants in Medical Oncology and Hematology (CMOH), a premier provider of comprehensive medical oncology services throughout the Philadelphia region for nearly 30 years and a national leader in the development of patient and physician-focused value-based cancer care delivery models, has joined The US Oncology Network (The Network).
BD (Becton, Dickinson and Company), a leading global medical technology company, today announced the completion of enrollment in the Lutonix below-the-knee (BTK) trial and plans to submit a pre-market approval application in late 2018.
Pharmaceutical Product Development, LLC (PPD), a leading global contract research organization (CRO), and Quotient Sciences (Quotient), a drug development services organization, today announced a new collaboration to accelerate pediatric drug development.
Pharma major Lupin Limited (Lupin) has made a foray into the over-the-counter (OTC) segment under the 'Lupin Life Consumer Healthcare' umbrella with the pan-India launch of Softovac. A 34-year old legacy brand, Softovac has been trusted by millions of consumers who suffer from constipation and irregular bowel habits.
Becton, Dickinson and Company a leading global medical technology company, along with Check-Points Health B.V., announced today that the companies obtained CE Mark for a next-generation molecular screening test for antibiotic-resistant carbapenemase-producing organisms (CPOs) on the fully-automated BD MAX™ System.
The WHISPER RCT is a multi-center, prospective, cross-over, randomized, and controlled study that evaluated the long-term safety and effectiveness of sub-perception SCS therapy. Participants had been implanted with an SCS system for an average of four years at the beginning of the study and were treated with both paresthesia and sub-perception therapy.
AstraZeneca and its global biologics research and development arm, MedImmune, today announced that the European Commission (EC) has approved Fasenra (benralizumab) as an add-on maintenance treatment in adult patients with severe eosinophilic asthma inadequately controlled despite high-dose inhaled corticosteroids plus long-acting beta-agonists.
Amgen and UCB (Euronext Brussels: UCB) today announced that the European Medicines Agency (EMA) has accepted the Marketing Authorization Application (MAA) for EVENITY™* (romosozumab) for the treatment of osteoporosis in postmenopausal women and in men at increased risk of fracture.
Acorda Therapeutics, Inc. reported AMPYRA® (dalfampridine) Extended Release Tablets, 10 mg unaudited net sales for the fourth quarter of 2017 of $166 million. Unaudited 2017 full-year net sales were $542 million, an increase of approximately 10% from 2016. Final results are subject to completion of the Company’s year-end audit.
Upadacitinib, an investigational oral agent engineered by AbbVie to selectively inhibit JAK1, is being studied as a once-daily therapy in atopic dermatitis and across multiple immune-mediated diseases
Amgen Astellas BioPharma K.K. and Astellas Pharma Inc. today announced the launch of Repatha® SC Injection 420 mg Auto Mini Doser (AMD), an additional dosage formulation to Repatha® SC Injection 140 mg Syringe and Pen.
Julphar (Gulf Pharmaceutical Industries), the largest generic pharmaceutical manufacturer in the MENA region, marked its entry into the men’s health sector with the launch of a new erectile dysfunction product, Dandasha (Tadalafil 20 mg), at the first Men’s Health Congress.
First and only approved disease-modifying medicine for people in the European Union (EU) with early primary progressive multiple sclerosis (PPMS)
Endo International plc ("Endo") today announced that its subsidiary, Endo Pharmaceuticals Inc.("EPI"), has received a grand jury subpoena from the United States Attorney's Office for the Southern District of Florida seeking documents and information relating to products containing oxymorphone.
Shionogi & Co., Ltd. (Head Office: Osaka, Japan; President and CEO: Isao Teshirogi, Ph.D.; hereafter "Shionogi") has signed collaborative agreement with PharmaIN Corporation (Head Office: Bothell, WA; President and CEO; Elijah Bolotin, Ph.D.; hereafter “PharmaIN”).